Navigation Links
Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments
Date:8/3/2009

erweight patients with type 2 diabetes. Results from BLOOM-DM will be submitted as a supplement to the lorcaserin NDA filing.
  • Announced a late-breaking poster presentation of positive results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight management, at the 69th Scientific Sessions of the American Diabetes Association. Lorcaserin patients achieved highly significant categorical and absolute weight loss in Year 1, and continued treatment with lorcaserin in Year 2 helped significantly more patients maintain their weight loss as compared to those on placebo. 66.4% of lorcaserin patients who completed one year of treatment according to the trial's protocol lost at least 5% of their weight and the average weight loss in this responder population was 26 pounds. Treatment with lorcaserin also resulted in highly significant improvements as compared to placebo in multiple secondary endpoints associated with cardiovascular risk. Lorcaserin was very well tolerated, did not result in increased risk of depression and was not associated with development of cardiac valvular insufficiency.
  • Ortho-McNeil-Janssen completed a Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of a single ascending dose of APD597 in healthy volunteers. Ortho-McNeil-Janssen has initiated another clinical trial evaluating multiple ascending doses of APD597.
  • Completed a public offering of 12.5 million shares of common stock, resulting in net proceeds to Arena of approximately $49.7 million.
  • Received net proceeds of $95.6 million from a $100.0 million secured loan provided by Deerfield Management. The outstanding principal accrues interest until maturity in June 2013 at a rate of 7.75% per annum. In connection with the loan, Arena issued Deerfield warrants for 28 million
    '/>"/>

  • SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine news :

    1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
    2. Arena Pharmaceuticals Announces Public Offering of Common Stock
    3. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
    4. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
    5. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
    6. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
    7. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
    8. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
    9. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
    10. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
    11. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/17/2014)... presence of chronic inflammation in benign prostate tissue ... and this association was found even in those ... a study published in Cancer Epidemiology, Biomarkers ... Association for Cancer Research. , An analysis of ... the placebo arm of the Prostate Cancer Prevention ...
    (Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
    (Date:4/17/2014)... Le Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, ... the April issue of Nature Reviews Microbiology ... Dr. McCullers, a world-renowned infectious disease specialist, ... the University of Tennessee Health Science Center, analyzed ... 1918, 1957 and 1968 pandemics, as well as ...
    (Date:4/17/2014)... (April 16, 2014) The cause of neuronal death ... study proposes that neurons may be mistaken for foreign ... similar to the way autoimmune diseases like type I ... cells. The study was published April 16, 2014, in ... and likely controversial, idea in Parkinson,s disease; but if ...
    (Date:4/17/2014)... An international team led by researchers at UC Davis ... plays a key role in cell division, also boosts ... the first time the complex has been shown to ... B1/Cdk1 an excellent target to control cellular energy production, ... was published online today in the journal Developmental ...
    Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
    ... of decline over past decade , , MONDAY, Oct. 15 (HealthDay ... across the United States, offering what an expert called a ... a new report, cancer death rates fell by 2.1 percent ... 1.1 percent annual decline recorded between 1993 and 2003. , ...
    ... 15, 2007 Post-hoc and other analyses of secondary ... Shire plc,s (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) ulcerative ... LIALDA in patients with mild to moderate ulcerative colitis. ... III, open-label 12-14 month extension study, are being presented ...
    ... LOGAN, Utah, Oct. 15 Facet Solutions, Inc. ... on the first cohort of,patients to receive its ... these patients at one year include a significant,decline ... function; and no,post-operative complications. Additionally, the first patient ...
    ... Patients with obstructive sleep apnea (OSA) who also ... continuous positive airway pressure (CPAP) relieves them of symptoms ... October 15 issue of the Journal of Clinical Sleep ... Sleep Center at Universitys Community Hospital in Tampa, Fla., ...
    ... schedules now routine and,the initial excitement over, lunches will ... a good time to re-evaluate menus and discuss healthier,choices ... The following are suggestions from the experts at ... nutritional impact. Add a,handful of trail mix and fresh ...
    ... have on average a 71 percent lower chance of ... lowest-rated hospitals across 18 procedures and conditions analyzed in ... issued today by HealthGrades, the healthcare ratings company. The ... of care between the highest-performing hospitals and all others, ...
    Cached Medicine News:Health News:U.S. Cancer Death Rate Continues to Fall 2Health News:U.S. Cancer Death Rate Continues to Fall 3Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 2Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 3Health News:New Analyses of long-term LIALDA (mesalamine) data presented at ACG 4Health News:Facet Solution's AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up 2Health News:Fresh, Tasty - Healthy - Lunch and Snack Ideas 2Health News:Mortality rates 71 percent lower at top-rated hospitals: HealthGrades 2008 hospital-quality study 2Health News:Mortality rates 71 percent lower at top-rated hospitals: HealthGrades 2008 hospital-quality study 3
    (Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
    (Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
    (Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
    Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
    ... 2012 On Jan. 23, IUE/CWA Local 81408, the ... Newtown Square eyeglass manufacturing facility, went on strike. This ... (IUE/CWA). Although 115 employees are covered under the bargaining ... According to company officials, each day, additional employees have ...
    ... Feb. 2, 2012    NorthCrest Medical Center will deploy ... ™ (SCM) acute care Electronic Health Record (EHR) to support ... (Logo: http://photos.prnewswire.com/prnh/20100901/CG58147LOGO ) ... across every measure of patient care, and Allscripts will help ...
    Cached Medicine Technology:Despite Employee Strike, Davis Vision Lab Continues to Fulfill Eyeglass Orders Without Service Interruption 2NorthCrest Medical Center Selects Allscripts Sunrise Electronic Health Record 2NorthCrest Medical Center Selects Allscripts Sunrise Electronic Health Record 3NorthCrest Medical Center Selects Allscripts Sunrise Electronic Health Record 4NorthCrest Medical Center Selects Allscripts Sunrise Electronic Health Record 5NorthCrest Medical Center Selects Allscripts Sunrise Electronic Health Record 6
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: